https://orcid.org/0009-0004-6497-7387
References
- Farahbakhshian S, Inocencio TJ, Poorman G, et al. The budget impact of enzyme replacement therapy in type 1 gaucher disease in the United States. J Med Econ. 2022;25(1):755–761.
- CEREZYME [Prescribing information] 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020367_S119lbl.pdf
- VPRIV [Prescribing information] 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022575lbl.pdf
- ELELYSO [Prescribing information] 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022458lbl.pdf
- CERDELGA [Prescribing information]. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205494orig1s000lbl.pdf
- Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with gaucher disease type 1 in the United States. Mol Genet Metab. 2016;117(2):95–103.
- Mistry PK, Lukina E, Ben Turkia H, et al. Clinical outcomes after 4.5 years of eliglustat therapy for gaucher disease type 1: phase 3 ENGAGE trial final results. Am J Hematol. 2021;96(9):1156–1165.
- Lukina E, Watman N, Dragosky M, et al. Eliglustat, an investigational oral therapy for gaucher disease type 1: phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 2014;53(4):274–276.
- Lukina E, Watman N, Dragosky M, et al. Outcomes after 8 years of eliglustat therapy for gaucher disease type 1: final results from the phase 2 trial. Am J Hematol. 2019;94(1):29–38. Jan
- Cox TM, Drelichman G, Cravo R, et al. Eliglustat maintains long-term clinical stability in patients with gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017;129(17):2375–2383.
- Mistry PK, Balwani M, Charrow J, et al. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the international collaborative gaucher group gaucher registry. Am J Hematol. 2020;95(9):1038–1046.
- Mistry PB, Sekulic D. Four-year real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the international collaborative gaucher group (ICGG) gaucher registry. J Inherited Metab Dis. 2022;45(S1):1–870.
- Belmatoug N, Di Rocco M, Fraga C, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 gaucher disease in Europe. Eur J Intern Med. 2017;37:25–32.
- Zavesca (Miglustat). Gaucher Disease News [cited 2022 Oct 12]. https://gaucherdiseasenews.com/zavesca-miglustat/
- Nalysnyk L, Sugarman R, Cele C, et al. Budget impact analysis of eliglustat for the treatment of gaucher disease type 1 in the United States. J Manag Care Spec Pharm. 2018;24(10):1002–1008. Oct
- CERDELGA®(eliglustat) capsules, for oral use. 2022. https://www.sanofi.us/dam/jcr:75688713-1a55-41d7-a05c-509257a8f26c/Cerdelga_Sanofi_US_CO_Form_11521.pdf
- Mistry PBJ, Sekulic D, editor. Four-year real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Society for the Study of Inborn Errors of Metabolism 2022.